University of Alberta researchers say GLP-1 drugs average 15% weight loss over 68 weeks, response varies
University of Alberta researchers say GLP-1 obesity drugs such as semaglutide are associated with about 15% average weight loss over 68 weeks when combined with lifestyle changes, but individual response varies. They are studying energy metabolism, body composition and metabolic adaptation to help explain why some people respond differently and how weight loss can be maintained.
A multidisciplinary team at the University of Alberta is examining why semaglutide-based obesity drugs, including Ozempic and Wegovy, produce different results across patients. The team notes that weekly GLP-1 use for 68 weeks, combined with lifestyle interventions, has been associated with an average 15% reduction in body weight. Semaglutide acts on the brain to increase fullness and reduce appetite, but the researchers say that response is not uniform and that energy metabolism may be an important part of the explanation.
The team published a recent review of studies on GLP-1 therapies and energy utilization. It found only a few studies examining how semaglutide affects resting energy use, and described the findings as neutral or inconclusive. The researchers point to metabolic adaptation, in which the body burns fewer calories than expected after weight loss. They are now recruiting participants with insulin resistance or diabetes who are about to start semaglutide, and will follow them for six months using whole-room indirect calorimetry.
The analysis situates GLP-1 drugs within a broader obesity-care context. The researchers say weight loss is only one measure of treatment benefit, because these medications have also been associated with improvements in quality of life, blood sugar and cholesterol markers, strength and overall health. At the same time, they list genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age and sex as possible factors shaping individual response. Energy use, including changes in fat and fat-free mass, is presented as one piece of that puzzle.
For patients and clinicians, the stakes are practical. The team says it is working to improve obesity care for people of all ages and to understand how weight loss can be maintained over time. By measuring energy utilization at rest, after eating and during exercise, the researchers are studying how semaglutide interacts with body composition and calorie burning. The source describes the work as part of efforts to develop better strategies for maintaining weight loss over the long term.
The report matters because people using GLP-1 drugs and their clinicians need to know that average results do not describe every patient, and individual energy metabolism may affect weight-loss response and maintenance.
Sources (1)
- [1]Original source(https://medicalxpress.com/news/2026-11-dont-glp1-obesity-drugs.html)